Pheochromocytoma Treatment

  • Carl D. Malchoff
  • Dougald MacGillivray
  • Steven Shichman
Chapter
Part of the Clinical Hypertension and Vascular Diseases book series (CHVD)

Abstract

Surgical resection remains the cornerstone of pheochromocytoma therapy. Because most of these tumors are benign and unifocal, resection produces a permanent cure. Prior to 1950, the operative mortality was more than 25% . With a better understanding of the potential complications that contribute to perisurgical mortality and with the introduction of α-adrenergic antagonists, the current surgical mortality is 2% or less. Surgical therapies continue to evolve and are supported by a greater choice of localizing techniques and treatment strategies both preoperatively and perioperatively. Combined surgical and medical therapy is required for the management of metastatic pheochromocytoma.

Keywords

Sodium Nitroprusside Laparoscopic Adrenalectomy Secondary Hypertension MIBG Uptake Adrenergic Blockade 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Duh Q-Y. Evolving surgical management for patients with pheochromocytoma. J Clin Endocrinol Metab 2001: 86: 1477–1479.PubMedCrossRefGoogle Scholar
  2. 2.
    Kvale W, Roth G, Manger W, Priestley T. Pheochromocytoma. Circulation 1956:14;622–630.PubMedCrossRefGoogle Scholar
  3. 3.
    Plouin P-F, Duclos J-M, Soppelsa F, Boublil G, Chatellier G. Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center. J Clin Endocrinol Metab 2001:86;1480–1486.PubMedCrossRefGoogle Scholar
  4. 4.
    Boutros A, Bravo E, Zanettin G, Straffon R. Perioperative management of 63 patients with pheochromocytoma. Cleve Clin J Med 1990:57;613–617.PubMedGoogle Scholar
  5. 5.
    Ulchaer J, Goldfarb D, Bravo E, Novick A. Successful outcomes of phcochromocytoma surgery in the modern era. J Urol 1999:61;764–767.Google Scholar
  6. 6.
    Knapp H, Fitzgerald G. Hypertensive crisis in prazosin-treated pheochromocytoma. S Med J 1984:77;535–536.CrossRefGoogle Scholar
  7. 7.
    Havkujm R, Cahow C, Kindre B. Advances in the diagnosis and treatment of pheochromocytoma. Arch Surg 1988:123;626–630.CrossRefGoogle Scholar
  8. 8.
    Ram C, Meese R, Hill S. Failure of alpha-methyltyrosine to prevent hypertensive crisis in pheochromocytoma. Arch Intern Med 1985:145;2114–2115.PubMedCrossRefGoogle Scholar
  9. 9.
    Steinsapir J, Can A, Prisant L, Bransome E. Metyrosine and pheochromocytoma. Arch Intern Med 1997:157;901–906.PubMedCrossRefGoogle Scholar
  10. 10.
    Perry R, Keiser H, Norton J, et al. Surgical management of pheochromocytoma with the use of metyrosine. Ann Surg 1990:212;621–628.PubMedCrossRefGoogle Scholar
  11. 11.
    Pogson G, Sharma J, Crouch T. Pulmonary edema with low-dose propranolol in pheochromocytoma. S Med J 1980:73;795–796.CrossRefGoogle Scholar
  12. 12.
    Wark J, Larkins R. Pulmonary oedema after propranolol therapy in two cases of phaeochromocytoma. BMJ 1978:1;1395–1396.PubMedCrossRefGoogle Scholar
  13. 13.
    Pearce CJ, Wallin JD. Labetalol and other agents that block both alpha- and betaadrenergic receptors. Cleve Clin J Med 1994:61;59–69.PubMedGoogle Scholar
  14. 14.
    Kanto J. Current status of labetalol, the first alpha- and beta-blocking agent. Int J Clin Pharmacol Ther Toxicol 1985:23;617–628.PubMedGoogle Scholar
  15. 15.
    Briggs R, Birtwell A, Pohl J. Hypertensive response to labetalol in phaeochromocytoma. Lancet 1978:13;1045–1046.CrossRefGoogle Scholar
  16. 16.
    Crawford GA, Gyory AZ, Gallery ED, Kelley D. HPLC of urinary catecholamines in the presence of labetalol, captopril, and alpha-methyldopa. J Clin Chem 1990:36;1849.Google Scholar
  17. 17.
    Khafagi FA, Shapiro B, Fig LM, Mallette S, Sisson JC. Labetalol reduces iodine131 MIBG uptake by pheochromocytoma and normal tissues. J Nucl Med 1989:30;481–489.PubMedGoogle Scholar
  18. 18.
    Brunjes S, Johns V, Crane M. Pheochromocytoma: postoperative shock. N Engl J Med 1960:262;393–396.PubMedCrossRefGoogle Scholar
  19. 19.
    Spark R, Connolly P, Gluckin D, White R, Sacks B, Landsberg L. ACTH secretion from a functioning pheochromocytoma. N Engl J Med 1979:23;416–418.CrossRefGoogle Scholar
  20. 20.
    Proye C, Huart J, Cuvillier X, Assez M, Gambardella B, Carnaille B. Safety of the posterior approach in adrenal surgery. Surgery 1993:114;1126–1131.PubMedGoogle Scholar
  21. 21.
    Gagner M, Lacroix A, Bolte E. Laparoscopic adrenalectomy in Cushing’s syndrome and pheochromocytoma. N Engl J Med 1992:327;1033.PubMedCrossRefGoogle Scholar
  22. 22.
    Brunt L, Moley J, Doherty G, Lairmore T, Debenedetti M, Quasebarth M. Outcome analysis in patients undergoing laparoscopic adrenalectomy for hormonally active adrenal tumors. Surgery 2001:130;629–635.PubMedCrossRefGoogle Scholar
  23. 23.
    Col V, Canniere L, Collard E, Michel L, Donckier J. Laparoscopic adrenalectomy for phaeochromocytoma: endocrinological and surgical aspects of a new therapeutic approach. Clin Endocrinol 1999:50;121–125.CrossRefGoogle Scholar
  24. 24.
    Janetschek G, Neumann H. Laparoscopic surgery for pheochromocytoma. Urol Clin N Am 2001:28;97–105.CrossRefGoogle Scholar
  25. 25.
    Shichman S, Herndon C, Sosa R, et al. Lateral transperitoneal laparoscopic adrenalectomy. World J Urol 1999:17;48–53.PubMedCrossRefGoogle Scholar
  26. 26.
    Salomon L, Rabii R, Soulie M, et al. Experience with retroperitoneal laparoscopic adrenalectomy for pheochromocytoma. J Urol 2001:165;1871–1874.PubMedCrossRefGoogle Scholar
  27. 27.
    Gagner M, Breton G, Pharand D, Pomp A. Is laparoscopic adrenalectomy indicated for pheochromocytomas? Surgery 1996:120;1076–1080.PubMedCrossRefGoogle Scholar
  28. 28.
    Li M. Fitzgerald P, Price D, Norton J. Iatrogenic pheochromocytomatosis: a previously unreported result of pheochromocytoma. Surgery 2001;1072–1077.Google Scholar
  29. 29.
    MacGillivray D, Whalen GF, Malchoff CD, Oppenheim DS, Shichman SJ. Laparoscopic resection of large adrenal tumors. Ann Surg Oncol 2002;130: 480–485.CrossRefGoogle Scholar
  30. 30.
    Averbuch S, Steakley C, Young R, et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Int Med 1988:102;267–273.Google Scholar
  31. 31.
    Pacak K, Fojok T, Goldstein D, et al. Radiofrequency ablation: a novel approach for treatment of metastatic pheochromocytoma. J Natl Cancer Institute 2001:2001; 648–649.Google Scholar
  32. 32.
    Adams S, Acker P, Lorenz M, Staib-Sebler E, Hor G. Radioisotope-guided surgery in patients with pheochromocytoma and intraoperative tumor localization with histopathologic findings. Cancer 2001:92;263–270.PubMedCrossRefGoogle Scholar
  33. 33.
    Keiser HR, Goldstein DS, Wade JL, Douglas FL, Averbuch SD. Treatment of malignant pheochromocytoma with combination chemotherapy. Hypertension 1985:7(Suppl I);18–24.CrossRefGoogle Scholar
  34. 34.
    Loh K, Fitzgerald P, Matthay K, Yeo P, Price D. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest 1997:11;648–658.Google Scholar
  35. 35.
    Sisson J, Shapiro B, Beierwaltes W, et al. Radiopharmaceutical treatment of malignant pheochromocytoma. J Nucl Med 1984:24;197–206.Google Scholar
  36. 36.
    Sisson JC, Shapiro B, Shulkin BL, Urba S, Zempel S, Spaulding S. Treatment of malignant pheochromocytomas with 131-I metaiodobenzylguanidine and chemotherapy. Am J Clin Oncol 1999:22;364–370.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • Carl D. Malchoff
  • Dougald MacGillivray
  • Steven Shichman

There are no affiliations available

Personalised recommendations